- Home
- MANE vs AUPH Comparison
MANE vs AUPH Comparison
Compare MANE & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MANE | AUPH |
|---|---|---|
| Founded | 2019 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | MANE | AUPH |
|---|---|---|
| Price | $80.18 | $16.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $78.33 | $17.25 |
| AVG Volume (30 Days) | 457.0K | ★ 1.1M |
| Earning Date | 03-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 2.07 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | N/A | $17.54 |
| Revenue Next Year | N/A | $15.74 |
| P/E Ratio | ★ N/A | $7.77 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $36.26 | $7.29 |
| 52 Week High | $75.95 | $16.54 |
Technical Indicators
Market Signals| Indicator | MANE | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 72.66 | 63.87 |
| Support Level | $54.23 | $14.56 |
| Resistance Level | N/A | $16.28 |
| Average True Range (ATR) | 6.51 | 0.52 |
| MACD | 1.12 | 0.11 |
| Stochastic Oscillator | 98.88 | 81.38 |
Price Performance
Historical ComparisonAbout MANE Veradermics Incorporated Common Stock
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.